A Response to the Letter to the Editor: "Durable Benefit Beyond Response: Reinterpreting Amivantamab Efficacy in METex14 NSCLC Subgroups"
- PMID: 41047189
- DOI: 10.1016/j.jtho.2025.07.003
A Response to the Letter to the Editor: "Durable Benefit Beyond Response: Reinterpreting Amivantamab Efficacy in METex14 NSCLC Subgroups"
Publication types
LinkOut - more resources
Full Text Sources